Last reviewed · How we verify
Intravitreal bevacizumab
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye.
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting abnormal blood vessel formation in the eye. Used for Age-related macular degeneration (AMD), wet form, Diabetic macular edema (DME), Retinal vein occlusion (RVO).
At a glance
| Generic name | Intravitreal bevacizumab |
|---|---|
| Also known as | Avastin |
| Sponsor | University of Sao Paulo |
| Drug class | VEGF inhibitor (monoclonal antibody) |
| Target | VEGF (Vascular Endothelial Growth Factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
When injected directly into the vitreous cavity of the eye, bevacizumab binds to and neutralizes VEGF, a key driver of pathological neovascularization in retinal diseases. By reducing VEGF signaling, it suppresses the growth of abnormal blood vessels and reduces vascular permeability, thereby slowing or halting disease progression in conditions characterized by excessive retinal angiogenesis.
Approved indications
- Age-related macular degeneration (AMD), wet form
- Diabetic macular edema (DME)
- Retinal vein occlusion (RVO)
- Proliferative diabetic retinopathy (PDR)
Common side effects
- Endophthalmitis (intraocular infection)
- Retinal detachment
- Cataract progression
- Intraocular pressure elevation
- Floaters/vitreous opacities
Key clinical trials
- Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety (NA)
- Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (PHASE3)
- Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema (PHASE1)
- Bevacizumab Treatment For Type 1 ROP (PHASE2)
- Comparison of Bevacizumab and Aflibercept in Treatment of Diabetic Macular Edema (NA)
- Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease (PHASE3)
- The Sahlgrenska Anti-VEGF Study (PHASE2)
- Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravitreal bevacizumab CI brief — competitive landscape report
- Intravitreal bevacizumab updates RSS · CI watch RSS
- University of Sao Paulo portfolio CI